A novel ginsenoside supplement, Redsenol-1 Plus, has been officially recognized by the National Cancer Institute (NCI) through its inclusion in the prestigious Drug Dictionary. The supplement, developed by Canada Royal Enoch Phytomedicine, stands out as the only product in its category to receive this significant acknowledgment.
The NCI Drug Dictionary listing provides a technical definition of Redsenol-1 Plus, detailing its composition of sixteen rare ginsenosides. Unlike traditional ginseng supplements that contain primarily large-molecule ginsenosides, this product features a highly bioactive profile with 20% rare ginsenoside concentration, compared to the standard 4% in conventional extracts.
The supplement's inclusion represents more than a bureaucratic milestone. It signals potential advancements in cancer supportive care, particularly in addressing cancer-related fatigue. The company is currently conducting a rigorous, triple-blind, placebo-controlled clinical trial to evaluate the supplement's efficacy in mitigating symptoms experienced by cancer patients during treatment.
Dr. Peihua Yu, the company's founder and CEO, emphasized the significance of the standardized definition, noting the importance of advancing scientific understanding of ginsenoside applications in cancer-related conditions.
The development underscores the growing scientific interest in plant-based compounds and their potential therapeutic applications, particularly in oncology support. By offering a more concentrated and bioavailable ginsenoside supplement, Canada Royal Enoch Phytomedicine is pushing the boundaries of natural health product research.
